3 Cannabis Stocks to Buy for Superior Returns in 2021

Amid the renewed interest in cannabis, these three stocks can deliver superior returns in 2021.

| More on:

The structural issues, such as lower-than-expected demand, oversupply, thriving black market sales, and slow rollout of retail stores in some Canadian provinces, had plagued the cannabis industry.

However, the victory of Joe Biden in the United States presidential elections last month and the legalization of cannabis in five U.S. states have brought some relief to the sector, with the industry benchmark Horizons Marijuana Life Sciences Index ETF rising close to 40% since the beginning of November. Amid the renewed interest, here are the three cannabis stocks to buy for superior returns in 2021.

Canopy Growth

Since the beginning of last month, Canopy Growth’s (TSX:WEED)(NYSE:CGC) stock has increased by 36%, driven by its impressive second-quarter performance and strengthening of the cannabis sector. In its September-ending quarter, the company’s top-line grew by 77% year-over-year, driven by growth in Canadian recreational and medical segments. The growth in its vape, value, and cannabis-infused beverage segments helped the company expand its market share in Canada’s recreational market to 15.5%.

Meanwhile, the United States offers enormous growth potential, with New Frontier Data projecting the legal cannabis sales to rise at an annualized rate of 18% over the next five years. So, Canopy Growth is focused on expanding its operations in the United States. In July, it had launched an e-commerce website.

Meanwhile, its subsidiary, BioSteel Sports Nutrition, has partnered with Manhattan Beer and Reyes Beer Division to expand its footprint. Further, the company plans to launch THC-infused beverages in the summer of 2021 in association with Acreage Holdings.

Despite the improvement in Canopy Growth’s margins, its adjusted EBITDA remained negative during the second quarter. Meanwhile, the company is taking initiatives, such as closing down some production facilities and cutting down on its SG&A (selling, general, and administrative) expenses, to move toward profitability.

The company’s management expects to report positive EBITDA in fiscal 2022. Given its high-growth potential and improving margins, I am bullish on Canopy Growth.

Aphria

When many cannabis stocks are struggling to become profitable, Aphria (TSX:APHA)(NASDAQ:APHA) has reported positive EBITDA for the previous six quarters. Further, the company has been expanding its market share in some major Canadian markets through its value propositions and product differentiation. Meanwhile, last month, the company announced an agreement to acquire SweetWater Brewing Company, which would mark Aphria’s entry into the lucrative American cannabis market.

In August, Aphria had also inked an agreement with Canndoc, a medical cannabis producer in Israel, to supply dried bulk flower for two years with an option to extend it for two more years. The company’s Aphria One facility had received European Union Good Manufacturing Practices certification in January, which could drive its cannabis sales to Europe. So, given its high growth prospects, strong balance sheet, and attractive valuation, I expect Aphria to deliver superior returns in 2021.

Green Thumb Industries

Green Thumb Industries (CNSX:GTII) is one of the top-performing cannabis stocks this year, with its stock price rising 118% year-to-date. In its recently announced third quarter, its top-line grew 131.1% to $157.1 million, driven by the expansion of its distribution of branded products, the addition of 15 new stores, and traffic growth.

Its adjusted EBITDA increased by over 285%, driven by higher sales and expansion of gross margin. Green Thumb also reported net profits of $9.6 million while posting positive cash flows for the third quarter in a row.

During the third quarter, the company started producing and distributing its branded products from its manufacturing facility in Oglesby, Illinois, after completing the initial construction phase. It also expanded its footprint to two new markets, New Jersey and Ohio.

Meanwhile, it also focuses on developing innovative products to expand its portfolio. Given its growth potential, I expect the rally in Green Thumb’s stock price to continue into 2021.

Fool contributor Rajiv Nanjapla has no position in the companies mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »